Yunpeng Pharmaceutical Group Co Ltd.

Primary objective: To evaluate the bioequivalence of the two preparations in fasting and fed state in healthy Chinese subjects through clinical trials, using furosemide tablets (trade name: LASIX, specification: 20 mg) from Validus Pharmaceuticals LLC as the reference preparation and furosemide tablets (20 mg) developed by Yunpeng Pharmaceutical Group Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and reference preparation in healthy Chinese subjects.

Main research purpose: According to the relevant provisions of bioequivalence test, empagliflozin tablets (trade name: Jardiance; specification: 25mg) with Boehringer Ingelheim International GmbH as the licensee were selected as the reference preparation, and the test preparation empagliflozin tablets (specification: 25mg) produced and provided by Yunpeng Pharmaceutical Group Co., Ltd. were subjected to human bioequivalence test on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation empagliflozin tablets (specification: 25mg) and the reference preparation empagliflozin tablets (trade name: Jardiance; specification: 25mg) by healthy volunteers.

Primary objective: To observe the pharmacokinetic characteristics of the test preparation hydrochlorothiazide tablets (specification: 25 mg; manufacturer: Yunpeng Pharmaceutical Group Co., Ltd.) and the reference preparation hydrochlorothiazide tablets (trade name: Esidrix®; specification: 25 mg; licensee: Laboratoires Juvise Pharmaceuticals) in Chinese healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation hydrochlorothiazide tablets and the reference preparation hydrochlorothiazide tablets (Esidrix®) in Chinese healthy subjects.